Grassley Investigates Merck/Schering’s Spending On Vytorin Promotion
This article was originally published in The Pink Sheet Daily
Executive Summary
Letter to CEOs asks for key opinion leaders’ names, how much they were paid.
You may also be interested in...
ACC Meeting ENHANCE Panel Calls For Return To Statins
The failed atherosclerosis study provides “no new evidence to support the use of this drug,” a cardiology panel says.
Lack Of Data Released From Merck/Schering-Plough Vytorin Trial Spurs House Inquiry
Companies also reject expert panel recommendation to change the primary endpoint for the ENHANCE trial.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.